Financing & the NHS Implications for HIV Nikhil Premchand Consultant Infectious Diseases

Similar documents
BHIVA antiretroviral treatment guidelines 2015

Pharmaceutical System in the UK

Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017

London Therapeu-c Tender Implementa-on: Guidance for Clinical Use. 14 January 2015

THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT. Esteban Burrone Head of Policy

Access to hepatitis medicines

Switching strategies and ARV treatment costs

Patient s perceptions of switching from Atripla to Truvada and generic efavirenz

What are the most promising opportunities for dose optimisation?

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

treatment passport 1

What's new in the WHO ART guidelines How did markets react?

Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430

The Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland

Update on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges

Cases from the Clinic(ians): Case-Based Panel Discussion

SHOULD A TRIAL EVALUATING THE USE OF LOW DOSE STAVUDINE BE CONDUCTED?

Rohit Malpani, Director Policy & Analysis Brussels, April 26, 2016.

Pharmacological considerations on the use of ARVs in pregnancy

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches

PrEP provision in healthcare settings: UK and France

Have new initiatives to improve availability made a difference?

UNDERSTANDING GP ATTITUDES TO CANCER PREVENTING DRUGS FEBRUARY 2017

Putting NICE guidance into practice. Resource impact report: Hearing loss in adults: assessment and management (NG98)

Persistent low level viraemia on third line ART

Access to newly licensed medicines. Scottish Medicines Consortium

Statistical issues in HIV trial design. Andrew Hill Senior Visiting Research Fellow Liverpool University

Improving Value in Chemotherapy

Patients First! Gilles Van Cutsem, MSF

Q&A on Second-Line HIV/AIDS Treatment

Simplifying HIV Treatment Now and in the Future

NHS England Impact Analysis of implementing NHS Diabetes Prevention Programme, 2016 to 2021

Forecasting pipeline ARVs. Joseph Perriëns Sandeep Juneja Aastha Gupta

2 Médecins Sans Frontières July 2007 Untangling the Web of Price Reductions

Treatment of chronic hepatitis C in HIV co-infected patients

Paediatric ART Working Group. guideline review meetings

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017

GPRM - Global Price Reporting Mechanism November Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009

Mortimer Market Centre, London. Dr Margaret Portman. Date : September 2016

SUBMISSION FROM THE NATIONAL AUTISTIC SOCIETY SCOTLAND

The impact of antiretroviral drugs on renal function

treatment VIRAL SUPPRESSION SUPPORT ART IS THE ONLY WAY TO CONTROL HIV TIPS FOR TAKING ART ADHERENCE Benefits of ART Start Know Your ARVs today ARVs

HIV and contraception the latest recommendations

What next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

HC 963 SesSIon november Department of Health. Young people s sexual health: the National Chlamydia Screening Programme

Comprehensive Guideline Summary

GPRM - Global Price Reporting Mechanism December Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2010

Buprenorphine used in the treatment of opioid dependence: availability and price

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

Incisionless surgery to correct protruding ears

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

European Guidelines. for the Clinical Management and Treatment of HIV Infected Adults

ART and Prevention: What do we know?

UK investment in HIV prevention 2015/16 and 2016/17. Examining UK expenditure on primary HIV prevention and HIV testing

Selecting an Initial Antiretroviral Therapy (ART) Regimen

HIV und AIDS- was gibt es Neues für die Arbeit vor Ort?

Resource impact report: Eating disorders: recognition and treatment (NG69)

Annex 1 Cost Benefit Analysis for UNITAID Patent Pool 2

Treatment Optimisation Community Condultation Feedback. KENLY SIKWESE AFRICAN COMMUNITY ADVISORY BOARD (AFROCAB) 3 rd May 2016

Is current first line ART good enough? Francois Venter Wits Reproductive Health & HIV Research Institute

Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)

The All Party Parliamentary Group on Skin Kensington Church Street, London W8 4DB

Cardiac Rehabilitation: Costing Tool Guidance

HIV - Therapy Principles

The ART of Managing Drug-Drug Interactions in Patients with HIV

Antiretroviral Dosing in Renal Impairment

Patents and licences on antiretrovirals: A snapshot

The Cost of Antiretrovirals

Genotypic Resistance Testing in Routine Care in South Africa:

UK Standards for Microbiology Investigations

Implanting pressure monitors in the pulmonary artery to monitor chronic heart failure

Dr Andrew Ustianowski

Procurement, selection, prequalification, pricing and monitoring of medicines

IATT Optimal List of Paediatric ARV Formulations: Background and Update

WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment

Hepatitis C: Policy in Action

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

11TH EDITION 11th EDITION JULY 2008

Continuing Education for Pharmacy Technicians

The Society welcomes the opportunity to respond the Department of Health s consultation on generic substitution.

Existing and most needed paediatric ARV formulations

Patient Forecasts for Pipeline ARVs: Adults

Clinical skills building - HIV drug resistance

Report by the Comptroller and. SesSIon January Improving Dementia Services in England an Interim Report

Constructing antiretroviral regimens to overcome imperfect adherence

HIV Clinical Nurse Specialist CCDHB Wellington

Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents

HIV Treatment: New and Veteran Drugs Classes

BHIVA Audit Survey of patient assessment and monitoring. starting ART from naïve. Survey of patient assessment and monitoring

Dr Marta Boffito. Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000:

Transplanting donated pancreatic islet cells for patients with type 1 diabetes

Census of the Radiotherapy Radiographic Workforce in the UK, 2016

Census of the Radiotherapy Radiographic Workforce in the UK, 2016

Building global capacity. Stefano Vella Center for Global Health Istituto Superiore di Sanità - Rome

INTRODUCTION TO THE MEDICINES PATENT POOL

More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD

Transaction Prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to July 2011

Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, User s Manual

Transcription:

Financing & the NHS Implications for HIV Nikhil Premchand Consultant Infectious Diseases

Disclosures Recipient of 2013 UK & Ireland Gilead Fellowship Award Unrestricted educational grant from Eumedica to attend ECCMID 2016

Time to get your cards out! Where do you work? Northern Ireland Scotland Wales England If none of the above, please put your hand up without holding a card.

The Financial Position - focus on England

The Economy Source: http://www.theguardian.com/uk-news/2015/jul/08/uk-economy-six-summerbudget-graphs-you-need-to-see Accessed 09/03/16.

The Economy Source: World Bank Data via Google Public Data http://tinyurl.com/z5bslfr Accessed 17/04/16.

Where the money goes 2014 Budget Source: http://www.theguardian.com/news/datablog/2014/mar/21/budget-2014-taxspending-visualised Accessed 09/03/16.

UK Healthcare spend Source: http://www.kingsfund.org.uk/projects/nhs-in-a-nutshell/nhs-budget Accesssed 09/03/16

Source: Kings Fund Website - http://www.kingsfund.org.uk/blog/2013/10/what-are-we-spending-english-nhs Accessed 07/11/13.

Local Government Budget Cuts Sources http://www.bbc.co.uk/news/uk-politics-34790102 Accessed 09/03/16 http://www.pulsetoday.co.uk/news/commissioning-news/government-announces-200mcuts-to-public-health-budget/20010183.fullarticle Accessed 18/04/16

UK Compared to other countries Sources: 2013 GDP Data http://www.kingsfund.org.uk/projects/nhs-in-a-nutshell/health-carespending-compared Accessed 09/03/16. Comparative Data - http://www.kingsfund.org.uk/blog/2016/01/how-does-nhsspending-compare-health-spending-internationally Accessed 09/03/16. Bankruptcy - http://www.cnbc.com/id/100840148 Accessed 09/03/16.

Where NHS money is spent: Source: http://www.mayden.co.uk/2011/05/nhs-spend-profile-2/ Accessed 07/11/13.

Proportion on staff Source: http://www.bbc.co.uk/news/uk-wales-30951803 Accessed 13/04/16.

Don t forget inflation Source: http://www.bbc.co.uk/news/business-34841952 - Accessed 09/03/16.

Source https://www.gov.uk/government/publications/review-body-on-doctors-anddentists-remuneration-43rd-report-2015 Accessed 13/04/16.

Concepts to be aware of: Tariffs Sexual health tariffs locally determined London has Integrated Sexual Health Tariff Source: https://www.gov.uk/government/publications/nhs-national-tariff-payment-system- 201617 Accessed 13/04/16 Further reading about London ISHT: http://sexualhealthtariff.pathwayanalytics.com/aboutthe-integrated-tariff/pathways-currencies-and-tariffs/tariff-prices Accessed 18/04/16

Market Forces Factor Weighting applied to activity payments including tariff and training payments to cover unavoidable costs Source:https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/509698/Annex_A_national_ prices_and_national_tariff_workbook.xlsx Accessed 13/04/16 Further reading about MFF: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/509770/guide_to_the_market_force s_factor.pdf Accessed 13/04/16

Pharmaceutical Price Regulation Scheme Voluntary agreement between pharmaceutical companies and DoH to ensure that safe and effective medicines are available on reasonable terms to the NHS and in maintaining a strong, efficient and profitable pharmaceutical industry. 5 years from 01/01/14 Limit growth in NHS branded medicine spend Complicated calculation basis Source:https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/28 2523/Pharmaceutical_Price_Regulation.pdf Accessed 13/04/16 Further reading about PPRS: http://www.abpi.org.uk/our-

What you do? Consultant Trainee (Foundation ST7) Industry/Other Student

NHS Provider Finances Source: http://www.independent.co.uk/news/uk/politics/nhs-hospitals-austerity-financesa6918896.html Original source Health Foundation. Accessed 09/03/16.

NHS Provider Finances Source: http://qmr.kingsfund.org.uk/2016/18/overview Accessed 09/03/16.

Hospital activity 2009/10 to 2014/15 Source: http://qmr.kingsfund.org.uk/2016/18/overview Accessed 09/03/16.

Source:: http://www.pharmaceutical-journal.com/news-and-analysis/news/nhs-drugspending-rises-by-8-to-155bn-in-england/20200096.article Accessed 13/04/16.

Global cost of Harvoni Source: http://esofosbuvir.com/harvoni-cost-in-usa-canada-europe-egypt-india/ Accessed 13/04/16. Also read: http://www.finance.senate.gov/ranking-members-news/wyden-grassleysovaldi-investigation-finds-revenue-driven-pricing-strategy-behind-84-000-hepatitis-drug

Population Structure Source: http://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/bulletins/nati onalpopulationprojections/2015-10-29accessed 09/03/16.

Source: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/469405/hiv_new_diagnoses_treat ment_and_care_2015_report20102015.pdf Accessed 09/03/16.

Consultant number increase Source: http://www.kingsfund.org.uk/projects/nhs-in-a-nutshell/nhs-staffing-numbers Accessed 09/03/16.

Source: https://www.gov.uk/government/publications/review-body-on-doctors-anddentists-remuneration-forty-third-report-2016 Accessed 13/04/16

Do you think doctors are worth what they re paid? Yes, of course! Not sure Absolutely not Don t care

Source: Figure 1 http://www.ons.gov.uk/ons/dcp171766_427045.pdf Accessed 09/03/16 Figure 5 http://www.nao.org.uk/wp-content/uploads/2010/12/1011491.pdf Accessed 07/11/13.

What is your Unique Selling Point (USP)?

Financial constraints will continue Enhanced self-care for patients with long term conditions New models of care needed Source: http://www.england.nhs.uk/wpcontent/uploads/2014/10/5yfv-web.pdf Accessed 04/03/15.

Other challenges Public expectations Worsening performance February 2016 4 hour A&E target worst month since 2004 (87.8%) 18 week target missed for third month in a row Cancer treatment commencement missed for 21 st of 22 months Staff morale Junior doctor strikes Fallout for next generation New consultant contract New AfC contract Source: https://www.england.nhs.uk/statistics/wp- content/uploads/sites/2/2015/08/monthly-performance-statistics-summary-2016- February-V0.1.pdf Accessed 14/04/16.

The Scottish Picture 2014/15 Source: http://www.audit-scotland.gov.uk/uploads/docs/report/2015/nr_151022_nhs_overview.pdf - Accessed 13/04/16.

What does this mean for HIV?

What changes have you had to make to your service? None at all Rationalised investigations Reduced staff numbers Changed opening hours

Slide courtesy of James Palmer, NHSE;; shown at Spring BHIVA 2015

Slide courtesy of James Palmer, NHSE;; shown at Spring BHIVA 2015

PbR and HARS Tariff for care exact amount to be decided Patients categorised by level of complexity / input needed Level determined by HARS return PHE algorithm determines categorisation High quality data is key

Other perspectives I think stable patients, which is probably 50-70% of most cohorts, are pretty simple after one year. Loads of that care can be very remotely delivered... They need to get a blood test somewhere, someone needs to review the result, someone needs to communicate that to them and they need to get their resupply of meds. That can all happen without coming to hospital... [However] I think there is reluctance amongst clinicians to lose their cohort because it is easy and satisfying work to do. Turkeys don t vote for Christmas do they? HIV Consultant comment in Commissioning London s HIV Services ;; CIVITAS 2011 Source: http://www.civitas.org.uk/pdf/hivcommission2011.pdf Accessed 07/11/13.

Source: https://www.england.nhs.uk/wp-content/uploads/2015/12/04.pb_.17.12.15- Allocations.pdf Accessed 13/04/16 Specialised Commissioning Budget Budget set for next 5 years across Specialised Commissioning Savings from within Major challenges from other areas (HCV, CF)

Could you save more money in your service? Yes, of course! Not sure Absolutely not Don t care

Evidence base to deliver greater value

Patent Expiry dates: 2015-2029 11 years (2015-2026) when many drugs are available as individual generics, but co-formulated versions are still on patent 2015: ZDV, 3TC, NVP, EFV, RTV already generic 2016: ABC, LPV/r 2017: TDF, ATV/r, DRV/r 2019: ABC/3TC (Kivexa) 2021: ETR 2024: TDF/FTC (Truvada) 2025: Raltegravir 2026: TDF/3TC/EFV (Atripla), TDF/FTC/RPV (Complera), 2029: ABC/3TC/DTG (Triumeq), TAF/FTC/ELV/c Slide courtesy of Andrew Hill Ref: Medecins Sans Frontieres 2014: Untangling the web of ARV price reductions

How much could generic HIV drugs cost? UK prices per person-year: Sterling Drug List price (NHS) -30% (Discount) -80% (Generic) Date Tenofovir 2880 2016 403 2017 FTC 1956 1369 274 now (3TC) Abacavir 2136 1495 300 2016 3TC 1608 1126 225 now Efavirenz 2400 1680 336 now Nevirapine 2040 1428 286 now Rilpivirine 2400 1680-2023 Darunavir/r 3600 2520 504 2017 Atazanavir/r 3636 2545 509 2017 Raltegravir 5652 3956-2025 Slide courtesy of Andrew Hill Sources: BNF 2014, Clinton Foundation 2013, MSF 2014

Predicted annual NHS costs of ARVs, 2015-2019 Option 1, patented: total cost of ARVs 2015-2019 = 2.41 billion Option 2, generics: total cost of ARVs 2015-2019 = 1.16 billion Potential saving = 1.25 billion Annual cost of ARVs ( million) 2015 2016 2017 2018 2019 Slide courtesy of Andrew Hill Year

Devolved nations Scotland: Scottish Medicines Consortium approve drugs No decision yet on PrEP, can be used in individual cases Wales: New drugs approved by All Wales Medicines Strategy Group (all ARV approved to date) Generally implements NICE guidance PrEP still being considered Northern Ireland:

Buyers Clubs 44/month Source: http://www.iwantprepnow.co.uk/ Accessed 13/04/16

Source: http://www.fixhepc.com/ Accessed 13/04/16 USD 1600 for 12 weeks of generic Sofosbuvir/Ledipasvir

Source: http://ilc-congress.eu/low-cost-generic-direct-acting-antiviral-treatment-hepatitisc-equivalent-branded-formulations/ Accessed 17/04/16

Summary Money is tight and will remain so No challenge is insurmountable, however the solutions may not always be palatable! Clinicians need to know costs and involve patients in the discussions about saving Need to deliver (much) more value and consider switching patients to generics Possibly need to be able to influence spend on issues such as PrEP if significant savings made elsewhere

Acknowledgements Birju Bartoli Andrew Freedman Andrew Hill Clifford Leen NHS England Commissioners

Any Questions?